Gracell Biotechnologies
A clinical-stage biotech company with mission to solve CAR-T industry hurdles.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $1.0b Valuation: $1.2b | Acquisition | |
| Total Funding | 000k | ||
Wellington Management(exited)
OrbiMed(exited)
Vivo Capital(exited)
Temasek(exited)
Lilly Asia Ventures(exited)
King Star Capital(exited)
Morningside(exited)
6 Dimensions Capital(exited)
Janus Henderson Investors(exited)
Logos Capital(exited)
Adage Capital(exited)
RA Capital Management(exited)
Exome Asset Management(exited)
TCGX(exited)
Pivotal Life Sciences(exited)
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (105226 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (123430 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 89317 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.